JLPC(SH:600513) Xin Lang Cai Jing·2026-01-07 06:02Group 1 - The core viewpoint of the articles indicates that Lianhuan Pharmaceutical's stock has experienced fluctuations, with a recent decline of 2.00% to 19.10 CNY per share, and a total market capitalization of 5.452 billion CNY [1] - As of September 30, the number of shareholders for Lianhuan Pharmaceutical increased by 54.72% to 46,600, while the average circulating shares per person decreased by 35.37% to 6,130 shares [2] - The company reported a revenue of 2.082 billion CNY for the first nine months of 2025, reflecting a year-on-year growth of 26.63%, but the net profit attributable to shareholders was a loss of 35.0621 million CNY, a decrease of 137.82% compared to the previous year [2] Group 2 - Lianhuan Pharmaceutical's main business revenue composition includes 70.01% from pharmaceuticals, 23.89% from medical devices, and 6.11% from other sources [1] - The company is categorized under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and chemical preparations, with involvement in various concept sectors such as antiviral drugs and innovative pharmaceuticals [1]